ENZ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENZ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Enzo Biochem's revenue per share for the three months ended in Oct. 2024 was $0.12. Enzo Biochem's revenue per share for the trailing twelve months (TTM) ended in Oct. 2024 was $0.59.
Warning Sign:
Enzo Biochem Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Enzo Biochem was -7.90% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -36.40% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -22.90% per year. During the past 10 years, the average Revenue Per Share Growth Rate was -12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Enzo Biochem's Revenue per Share or its related term are showing as below:
During the past 13 years, Enzo Biochem's highest 3-Year average Revenue Per Share Growth Rate was 28.90% per year. The lowest was -36.40% per year. And the median was 3.95% per year.
The historical data trend for Enzo Biochem's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzo Biochem Annual Data | |||||||||||||||||||||
Trend | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | Jul21 | Jul22 | Jul23 | Jul24 | |||||||||||
Revenue per Share | Get a 7-Day Free Trial | 1.59 | 2.44 | 0.67 | 0.63 | 0.63 |
Enzo Biochem Quarterly Data | ||||||||||||||||||||
Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | Apr24 | Jul24 | Oct24 | |
Revenue per Share | Get a 7-Day Free Trial | 0.16 | 0.17 | 0.16 | 0.15 | 0.12 |
For the Diagnostics & Research subindustry, Enzo Biochem's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's PS Ratio distribution charts can be found below:
* The bar in red indicates where Enzo Biochem's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Enzo Biochem's Revenue Per Share for the fiscal year that ended in Jul. 2024 is calculated as
Revenue Per Share (A: Jul. 2024 ) | = | Revenue (A: Jul. 2024 ) | / | Shares Outstanding (Diluted Average) (A: Jul. 2024 ) |
= | 31.907 | / | 50.902 | |
= | 0.63 |
Enzo Biochem's Revenue Per Share for the quarter that ended in Oct. 2024 is calculated as
Revenue Per Share (Q: Oct. 2024 ) | = | Revenue (Q: Oct. 2024 ) | / | Shares Outstanding (Diluted Average) (Q: Oct. 2024 ) |
= | 6.213 | / | 52.244 | |
= | 0.12 |
Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzo Biochem (NYSE:ENZ) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Enzo Biochem's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Steven J Pully | director | 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042 |
James G. Wolf | 10 percent owner | 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455 |
Hamid Erfanian | officer: Chief Executive Officer | 527 MADISON AVENUE, NEW YORK NY 10022 |
Patricia Eckert | officer: Interim CFO | C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735 |
Kara Cannon | officer: Chief Operating Officer | 527 MADISON AVE, NEW YORK NY 10022 |
Bradley Louis Radoff | director | 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098 |
David Bench | officer: CHIEF FINANCIAL OFFICER | ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
Harbert Discovery Fund, Lp | 10 percent owner | HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
Ian B. Walters | director | ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
Mary Tagliaferri | director | 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
Clemens Peter J Iv | 10 percent owner | 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069 |
Rebecca J. Fischer | director | ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
Fabian Blank | 10 percent owner, other: See Remarks | ROEMERSTRASSE 6, BAD BERTRICH 2M 56864 |
Harbert Management Corp | 10 percent owner | 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
Harbert Discovery Co-investment Fund I Gp, Llc | 10 percent owner | 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
From GuruFocus
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
By sperokesalga sperokesalga • 03-21-2023
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.